The U.S. Food and Drug Administration (FDA) is informing the public that we are aware of results from clinical trials conducted inside and outside the United States that found that patients treated with Revlimid (lenalidomide) may be at an increased risk of developing new types of cancer compared to patients who did not take the drug.
FDA is currently reviewing all available information on this potential risk and will communicate any new recommendations once it has completed its review.
At this time, FDA recommends that patients continue their Revlimid treatment as prescribed by their healthcare provider.
The benefits and the risks of Revlimid should be carefully weighed when prescribing this drug. Healthcare professionals should be aware that Revlimid may increase the risk of developing another type of cancer.
Revlimid is used to treat a type of blood disorder known as myelodysplastic syndrome. Revlimid is also used along with other drugs to treat people with the cancer known as multiple myeloma.
For more information, please visit: Revlimid
Drug Safety and Availability > FDA Drug Safety Communication: Ongoing safety review of Revlimid (lenalidomide) and possible increased risk of developing new malignancies
.png)
No hay comentarios:
Publicar un comentario